Pfizer (PFE) Amortization - Intangibles (2009 - 2026)

Pfizer (PFE) has reported Amortization - Intangibles for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Amortization - Intangibles fell 2.15% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was $4.8 billion, a 37.03% decrease from a year earlier, with the FY2025 full-year figure at $4.9 billion, down 7.79% from the prior year.
• Amortization - Intangibles was $1.2 billion for Q2 2026 at Pfizer, roughly flat from $1.2 billion in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $3.9 billion in Q3 2024 and troughed at $822.0 million in Q3 2022.
• A 5-year average of $1.4 billion and a median of $1.2 billion in 2025 frame the typical range for Amortization - Intangibles.
• Across the five-year window, Amortization - Intangibles soared 44.04% in 2023 and plunged 68.86% in 2025, its largest moves.
• Over 5 years, Amortization - Intangibles stood at $822.0 million in 2022, then soared by 54.14% to $1.3 billion in 2023, then soared by 209.94% to $3.9 billion in 2024, then tumbled by 68.68% to $1.2 billion in 2025, then declined by 3.66% to $1.2 billion in 2026.
• The last three Amortization - Intangibles figures came in at $1.2 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.